Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis

• Published in: Tumor biology Vol. 36; no. 2; pp. 701 - 709
• Main Authors: Zhai, Jin-Hai, Gu, Wen-Chao, Xu, Xiao-Lin, Wu, Jiang, Hu, Xue-Jun, Hou, Ke-Zhu
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 01.02.2015
• Subjects: AC133 Antigen; Antigens, CD - biosynthesis; Antigens, CD - genetics; Asian Continental Ancestry Group; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - genetics; Cancer; Chemotherapy; Disease-Free Survival; Gene expression; Gene Expression Regulation, Neoplastic; Glycoproteins - biosynthesis; Glycoproteins - genetics; Humans; Medical diagnosis; Meta-analysis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Neoplasms - radiotherapy; Patients; Peptides - genetics; Prognosis; Radiology
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-014-2251-z

Many studies evaluated the correlations of CD133 expression with the clinical outcomes in patients treated with chemoradiotherapy (CRT) but yielded controversial results. This meta-analysis was performed to identify the impacts of CD133 expression on the prognosis of cancer patients treated with CRT. Electronic databases updated up to March 2014 were searched to find relevant studies. Relevant literatures without any language restrictions were searched via electronic databases as follows: Web of Science (1945 ~ 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 ~ 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013). STATA software was used for the current meta-analysis. Hazard ratios (HR) and its corresponding 95% confidence interval (95% CI) were calculated. Six studies were identified with a total of 470 cancer patients treated with CRT. The meta-analysis results showed that CD133-positive patients had poorer overall survival (OS) than that of CD133-negative patients (HR = 2.13, 95% CI = 1.20 ~ 3.07, P < 0.001). Furthermore, CD133-positive patients displayed shorter disease-free survival (DFS) than that of CD133-negative patients (HR = 1.74, 95% CI = 0.08 ~ 3.40, P = 0.039). Ethnicity-stratified analysis indicated that CD133 expression positively correlated with shorter OS among the Japanese, Chinese, and Spanish populations (all P < 0.05). In conclusion, our findings suggest that CD133 expression may be positively correlated with poorer prognosis in cancer patients treated with CRT.